Mirtazapina Alter (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Alter, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is prescribed for the treatment of major depressive disorder in adults, helping to improve mood, sleep and appetite.

GNH USA supplies Mirtazapina Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for this antidepressant medication.

Mirtazapine is used primarily in the management of depressive disorders, acting on noradrenergic and serotonergic pathways.

- Major depressive disorder: alleviates depressive symptoms and improves functional outcomes. - Depression with anxiety symptoms: reduces anxiety and improves overall mood. - Depression with insomnia: promotes sleep and helps restore normal sleep patterns.

Common Side Effects: - Sedation: drowsiness, especially after the first doses. - Increased appetite: may lead to weight gain. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells. - Seizures: risk of convulsive episodes. - Severe hypersensitivity: rash, swelling, or anaphylaxis. - Hepatotoxicity: liver enzyme elevations or injury. - Emergence of suicidal thoughts: particularly early in treatment.

Mirtazapine requires careful clinical monitoring.

- Hepatic function: assess liver status before initiating therapy. - Suicidal ideation: monitor for worsening depression or suicidal thoughts. - Cardiovascular disease: use cautiously in patients with heart conditions. - Discontinuation: avoid abrupt cessation to reduce withdrawal risk. - Renal impairment: consider dose adjustment in severe kidney disease. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Mirtazapine may interact with several medications.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants (e.g., alcohol, benzodiazepines): additive sedation. - Strong CYP2D6 inhibitors (e.g., fluoxetine): increased mirtazapine levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible enhanced hypotensive effect. - Anticholinergic drugs: may increase dry mouth and constipation.